Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer (NQF 0387)

EMeasure Name	Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	**EMeasure Id**	Pending
Version Number	1	**Set Id**	Pending
Available Date	No information	**Measurement Period**	January 1, 20xx through December 31, 20xx
Measure Steward	American Medical Association – Physician Consortium for Performance Improvement		
Endorsed by	National Quality Forum		
Description	Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period.		
Measure scoring	Proportion		
Measure type	Process		
Rationale	Despite evidence suggesting the role of adjuvant endocrine therapy in lowering the risk of tumor recurrence, many female patients who should be receiving this therapy are not. This measure assesses whether patients with a certain stage of breast cancer (IC through IIIC) and ER/PR+ are currently receiving the therapy. There are allowable medical, patient, and system reasons to document instances in which a woman with stage IC through IIIC, ER/PR+ may not be a candidate for the therapy.		
Clinical Recommendation Statement	Adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer should include an aromatase inhibitor in order to lower the risk of tumor recurrence. Aromatase inhibitors are appropriate as initial treatment for women with contraindications to tamoxifen. For all other postmenopausal women, treatment options include 5 years of aromatase inhibitors treatment or sequential therapy consisting of tamoxifen (for either 2 to 3 years or 5 years) followed by aromatase inhibitors for 2 to 3, or 5 years (ASCO guidelines include narrative rankings) (ASCO). Patients intolerant of aromatase inhibitors should receive tamoxifen. Women with hormone receptor–negative tumors should not receive adjuvant endocrine therapy (ASCO guidelines include narrative rankings) (ASCO). Patients with invasive breast cancers that are estrogen or progesterone receptor positive should be considered for adjuvant endocrine therapy regardless of patient age, lymph node status, or whether or not adjuvant chemotherapy is to be administered (Category 2A) (NCCN). The most firmly established adjuvant endocrine therapy is tamoxifen for both premenopausal and postmenopausal women. Prospective, randomized trials demonstrate that the optimal duration of tamoxifen appears to be five years. In patients receiving both tamoxifen and chemotherapy, chemotherapy should be		

	given first, followed by sequential tamoxifen. Several studies have evaluated aromatase inhibitors in the treatment of postmenopausal women with early-stage breast cancer (Category 2A) (NCCN).
References	
Definitions	

Table of Contents

Please refer to the spreadsheet for this measure for detail regarding data criteria and code lists.

Population criteria

- **Initial Patient Population** =
    - AND: “Patient characteristic: birth date” (age) >= 18 years;
    - AND:
        - OR: “Diagnosis active: breast cancer”;
        - OR: “Diagnosis inactive: breast cancer history”;
    - AND: >= 2 count(s) of “Encounter: encounter office visit”;
- **Denominator** =
    - AND: All patients in the initial patient population;
    - AND: “Patient characteristic: gender”, value = “female”;
    - AND: “Procedure result: breast cancer Stage IC-IIIC”;
    - AND: “Procedure result: breast cancer ER or PR positive”;
- **Numerator** =
    - OR: “Medication order: tamoxifen or aromatase inhibitor therapy”;
    - OR: “Medication active: tamoxifen or aromatase inhibitor therapy”;
- **Exclusions** =
    - OR: “Medication intolerance: tamoxifen or aromatase inhibitor therapy”;
    - OR: “Medication adverse event: tamoxifen or aromatase inhibitor therapy”;
    - OR: “Medication allergy: tamoxifen or aromatase inhibitor therapy”;
    - OR: “Medication active: gonadotropin-releasing hormone analogue medication”;
    - OR: “Procedure performed: bilateral oophorectomy”;
    - OR: “Procedure performed: radiation therapy”;
    - OR: “Procedure performed: chemotherapy”;
    - OR: “Diagnosis active: metastatic sites common to breast cancer”;
    - OR: “Medication not done: system reason”;
    - OR: “Medication not done: patient reason”;
    - OR: “Medication not done: medical reason”;

<u>Data criteria</u> (QDS Data Elements)

- **Initial Population Criteria =**
    - "Patient characteristic: birth date" using "birth date code list" before the beginning of the "measurement period";
    - "Diagnosis active: breast cancer" using "breast cancer code list grouping" before or simultaneously to "Encounter: encounter office visit";
    - "Diagnosis inactive: breast cancer history" using "breast cancer history code list grouping" before or simultaneously to "Encounter: encounter office visit";
    - "Encounter: encounter office visit" using "encounter office visit code list" during the "measurement period";
- **Denominator =**
    - All patients in the initial patient population;
    - "Patient characteristic: gender" using "gender code list" before or simultaneously to "Encounter: encounter office visit";
    - "Procedure result: breast cancer Stage IC-IIIC" using "breast cancer Stage IC-IIIC code list" before or simultaneously to "Encounter: encounter office visit";
    - "Procedure result: breast cancer ER or PR positive" using "breast cancer ER or PR positive code list" before or simultaneously to "Encounter: encounter office visit";
- **Numerator =**
    - "Medication order: tamoxifen or aromatase inhibitor therapy" using "tamoxifen or aromatase inhibitor therapy code list" during the "measurement period";
    - "Medication active: tamoxifen or aromatase inhibitor therapy" using "tamoxifen or aromatase inhibitor therapy code list" during the "measurement period";
- **Exclusions =**
    - "Medication intolerance: tamoxifen or aromatase inhibitor therapy" using "tamoxifen or aromatase inhibitor therapy code list" during the "measurement period";
    - "Medication adverse event: tamoxifen or aromatase inhibitor therapy" using "tamoxifen or aromatase inhibitor therapy code list" during the "measurement period";
    - "Medication allergy: tamoxifen or aromatase inhibitor therapy" using "tamoxifen or aromatase inhibitor therapy code list" during the "measurement period";
    - "Medication active: gonadotropin-releasing hormone analogue medication" using "gonadotropin-releasing hormone analogue medication code list" before or simultaneously to "encounter: encounter office visit";
    - "Procedure performed: bilateral oophorectomy" using "bilateral oophorectomy code list grouping" before or simultaneously to "encounter: encounter office visit";
    - "Procedure performed: radiation therapy" using "radiation therapy code list grouping" before or simultaneously to "encounter: encounter office visit";
    - "Procedure performed: chemotherapy" using "chemotherapy code list grouping" before or simultaneously to "encounter: encounter office visit";
    - "Diagnosis active: metastatic sites common to breast cancer" using "metastatic sites common to breast cancer code list grouping" before or simultaneously to "encounter: encounter office visit";

- "Medication not done: system reason" using "system reason code list" for "medication order: tamoxifen or aromatase inhibitor therapy" OR "medication active: tamoxifen or aromatase inhibitor therapy";
- "Medication not done: patient reason" using "patient reason code list" for "medication order: tamoxifen or aromatase inhibitor therapy" OR "medication active: tamoxifen or aromatase inhibitor therapy";
- "Medication not done: medical reason" using "medical reason code list" for "medication order: tamoxifen or aromatase inhibitor therapy" OR "medication active: tamoxifen or aromatase inhibitor therapy";

Summary Calculation

Calculation is generic to all measures:

- Calculate the final denominator by adding all that meet denominator criteria.
- Subtract from the final denominator all that do not meet numerator criteria yet also meet exclusion criteria. Note some measures do not have exclusion criteria.
- The performance calculation is the number meeting numerator criteria divided by the final denominator.
- For measures with multiple patient populations, repeat this process for each patient population and report each result separately.
- For measures with multiple numerators, calculate each numerator separately within each population using the paired exclusion.

Measure set	CLINICAL QUALITY MEASURE SET 2011-2012